ANTINEOPLASTIC AGENTS, HORMONAL

Clinical trials for ANTINEOPLASTIC AGENTS, HORMONAL explained in plain language.

Never miss a new study

Get alerted when new ANTINEOPLASTIC AGENTS, HORMONAL trials appear

Sign up with your email to follow new studies for ANTINEOPLASTIC AGENTS, HORMONAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Could a targeted drug delay prostate cancer progression?

Disease control Ongoing

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

Matched conditions: ANTINEOPLASTIC AGENTS, HORMONAL

Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Jul 02, 2026 01:00 UTC

ANTINEOPLASTIC AGENTS, HORMONAL

Get alerted when new ANTINEOPLASTIC AGENTS, HORMONAL trials appear

Could a targeted drug delay prostate cancer progression?